OFI Invest Asset Management Boosts Amgen Stock Position

Investment firm increases stake in biotech giant by over 100% in Q4 2025

Apr. 10, 2026 at 9:55am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, interlocking metal gears and machinery, representing the complex financial infrastructure and institutional investment that supports the pharmaceutical industry.

A major investment firm's substantial increase in its Amgen holdings signals continued institutional confidence in the biotech company's long-term growth potential.Thousand Oaks Today

OFI Invest Asset Management, a major investment firm, significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter of 2025, according to a recent SEC filing. The firm added over 5,200 shares to its Amgen holdings, growing its position by 113% compared to the prior quarter.

Why it matters

Amgen is one of the world's largest biotechnology companies, with a focus on developing innovative therapies for serious illnesses. This sizable investment by OFI Invest Asset Management suggests the firm sees strong growth potential in Amgen's pipeline and business outlook.

The details

According to the SEC filing, OFI Invest Asset Management now owns 9,913 shares of Amgen stock, valued at approximately $3.25 million as of the end of 2025. The firm's increased stake in Amgen comes as the biotech company continues to advance its drug development programs and navigate a competitive pharmaceutical landscape.

OFI Invest Asset Management filed the 13F report disclosing the Amgen stake increase on April 10, 2026.
The firm grew its Amgen position by 113% in the fourth quarter of 2025 compared to the prior quarter.

The players